CCR1 antagonism has been seen as a potential strategy for diseases such as rheumatoid arthritis and multiple sclerosis; however, clinical trials for the antagonists developed have generally failed in phase 2 after being found safe, but not efficacious for treatment27. This evidence concerns the gene CCR1 and rheumatoid arthritis.